Skye Bioscience, Inc.
SKYE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001516551
In the last 90 days, Skye Bioscience, Inc. insiders filed 0 open-market purchases and 3 sales; 42 institutions reported holding it in 13F filings for Q2 2026, worth $11.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $444.6K in total
- 3
- 13F holdersQ2 2026, +3 vs. previous quarter
- 42
- 13F valueReported value at the end of Q2 2026
- $11.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SKYE, Q2 2026
No superinvestor reported holding SKYE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Skye Bioscience, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:31 PM ET | Sep 22-23 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −148.1K | $1.62 | −$239.6K | −100.0%0 after | 4 lotsDuplicate filing |
| Sep 24, 2026 (view filing)4:29 PM ET | Sep 22-23 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −148.1K | $1.62 | −$239.6K | −100.0%0 after | 4 lots |
| Sep 18, 2026 (view filing)6:39 PM ET | Sep 16 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −33.9K | $1.91 | −$64.7K | −85.8%5.62K after | 2 lotsDuplicate filing |
| Sep 18, 2026 (view filing)6:37 PM ET | Sep 16 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −33.9K | $1.91 | −$64.7K | −85.8%5.62K after | 2 lots |
| Aug 20, 2026 (view filing)5:59 PM ET | Aug 18-20 | 2 days | Schwab Andrew J.Director, 10% Owner | SSale | −375.8K | $0.3733 | −$140.3K | −4.6%7.85M after | 9 lotsDuplicate filing |
| Aug 20, 2026 (view filing)5:57 PM ET | Aug 18-20 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −375.8K | $0.3733 | −$140.3K | −4.6%7.85M after | 9 lots |
| Aug 22, 2025 (view filing)7:05 PM ET | Aug 21-22 | 1 day | Rocklage Scott M and 7 others10% Owner | SSale | −231.4K | $3.46 | −$800.5K | −80.1%57.5K after | 4 lotsDuplicate filing |
| Aug 22, 2025 (view filing) | Aug 21-22 | 1 day | Schwab Andrew J.Director, 10% Owner | SSale | −231.4K | $3.46 | −$800.5K | −80.1%57.5K after | 4 lots |
| Feb 28, 2025 (view filing) | Nov 15-18, 2024 | 105 days | Arsenault Kaitlyn MelanieChief Financial Officer | SSale | −43.2K | $4.99 | −$215.8K | −20.5%167.5K after | Amended2 lots |
| Nov 20, 2024 (view filing) | Nov 15-18 | 5 daysLate | Diep Tuan TuChief Development Officer | SSale | −19.6K | $4.99 | −$97.7K | −19.2%82.3K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Skye Bioscience, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 9,681,763 | $6.71M | 2.33% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 2,007,704 | $1.39M | 0.86% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 1,575,243 | $1.09M | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 763,882 | $529.4K | 0.00% | −575−0.1% | Reduced |
| Sphera Funds Management Ltd. | 678,928 | $470.7K | 0.07% | 00.0% | Unchanged |
| Platinum Investment Management Ltd | 233,095 | $161.6K | 0.04% | 00.0% | Unchanged |
| BlackRock, Inc. | 232,874 | $161.5K | 0.00% | −53,257−18.6% | Reduced |
| Geode Capital Management, LLC | 218,055 | $151.2K | 0.00% | −59,201−21.4% | Reduced |
| Millennium Management LLC | 198,524 | $137.6K | 0.00% | −59,676−23.1% | Reduced |
| Vanguard Fiduciary Trust Co | 104,229 | $72.2K | 0.00% | 00.0% | Unchanged |